Seeking Alpha

AstraZeneca well positioned to join cancer immunotherapy race: Reuters

  • AstraZeneca (AZN +0.5%) may be a step behind Roche (RHHBY.OB +0.9%), Bristol-Myers (BMY +0.3%), and Merck (MRK -1.3%) when it comes to developing immunotherapies to treat cancer, but "the field is still very open for combinations and [AZN is] very much in the race," the company's head of biologics Bahija Jallal says.
  • The "breadth" of AZN's pipeline and the "pace of cancer drug development" may help AZN catch up to industry leaders quickly, Reuters notes.
  • One promising candidate is the PD-L1 blocker MEDI4376 which may prove most effective when paired with other drugs such as tremelimumab which "works in a similar way to BMY's Yervoy."
  • Late last month, Roche reported positive results for its PD-LI drug MPDL3280A in NSCLC.
Comments (1)
  • 5967241
    , contributor
    Comments (89) | Send Message
     
    AZN is always a step behind other. Take the example of one of their recent purchases--> OMTH which doesn't have an approved drug, patent or a pipeline. Half a billion thrown into garbage even after knowing that the competitors are already way ahead of them.
    14 Oct 2013, 02:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs